Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2003 1
2006 1
2007 1
2008 2
2010 1
2011 1
2013 1
2014 1
2015 1
2016 6
2017 8
2018 11
2019 6
2020 4
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

39 results
Results by year
Filters applied: . Clear all
Page 1
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.
Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O'Malley DM, Backes F, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi KS, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD. Fader AN, et al. Among authors: litkouhi b. J Clin Oncol. 2018 Jul 10;36(20):2044-2051. doi: 10.1200/JCO.2017.76.5966. Epub 2018 Mar 27. J Clin Oncol. 2018. PMID: 29584549 Clinical Trial.
Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.
Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O'Malley DM, Backes FJ, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD. Fader AN, et al. Among authors: litkouhi b. Clin Cancer Res. 2020 Aug 1;26(15):3928-3935. doi: 10.1158/1078-0432.CCR-20-0953. Epub 2020 Jun 29. Clin Cancer Res. 2020. PMID: 32601075
Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma.
Deshmukh U, Black J, Perez-Irizarry J, Passarelli R, Levy K, Rostkowski A, Hui P, Rutherford TJ, Santin AD, Azodi M, Silasi DA, Ratner E, Litkouhi B, Schwartz PE. Deshmukh U, et al. Among authors: litkouhi b. Reprod Sci. 2019 May;26(5):600-608. doi: 10.1177/1933719118778801. Epub 2018 May 29. Reprod Sci. 2019. PMID: 29843577
PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
Bonazzoli E, Cocco E, Lopez S, Bellone S, Zammataro L, Bianchi A, Manzano A, Yadav G, Manara P, Perrone E, Haines K, Espinal M, Dugan K, Menderes G, Altwerger G, Han C, Zeybek B, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. Bonazzoli E, et al. Among authors: litkouhi b. Gynecol Oncol. 2019 Apr;153(1):158-164. doi: 10.1016/j.ygyno.2019.01.002. Epub 2019 Jan 7. Gynecol Oncol. 2019. PMID: 30630630 Free PMC article.
Ten-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and Outcomes.
Feinberg J, Albright B, Black J, Lu L, Passarelli R, Gysler S, Whicker M, Altwerger G, Menderes G, Hui P, Santin AD, Azodi M, Silasi DA, Ratner ES, Litkouhi B, Schwartz PE. Feinberg J, et al. Among authors: litkouhi b. Gynecol Obstet Invest. 2019;84(3):290-297. doi: 10.1159/000493132. Epub 2019 Jan 2. Gynecol Obstet Invest. 2019. PMID: 30602164 Free article.
Adjuvant Therapy Use and Survival in Stage II Endometrial Cancer.
Lester-Coll NH, Young MR, Park HS, Ratner ES, Litkouhi B, Damast S. Lester-Coll NH, et al. Among authors: litkouhi b. Int J Gynecol Cancer. 2017 Nov;27(9):1904-1911. doi: 10.1097/IGC.0000000000001095. Int J Gynecol Cancer. 2017. PMID: 28763364
39 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page